Feasibility of a Newborn Screening for Spinal Muscular Atrophy (SMA) in France: DEPISMA Prefigurator Project in Grand-Est and Nouvelle-Aquitaine

Spinal muscular atrophy (SMA) is a genetic disease of the nervous system that affects about 1 in 7,0001.2 births and results in very high mortality for patients with the disease. There are about 120 n...

Lead sponsor: University Hospital, Strasbourg, France•39 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Vincent LAUGEL

CONTACT

33388127743 [email protected]

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment220,000

Start dateDec 2022

Last updatedSep 8, 2023

Condition

Feasibility of Neonatal Screening for Spinal Amyotrophy

Locations shown

Ch de Colmar - Hôpital Louis Pasteur

Colmar, Alsace

Hôpital Albert Schweitzer - Clinique Du Diaconat de Colmar

Colmar, Alsace

Ch de Haguenau

Haguenau, Alsace

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 8, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions